EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study

John E J Rasko iD, Benjamin J Samelson-Jones, Lindsey A George, Adam Giermasz, Jonathan M Ducore, Jerome M Teitel, Catherine E McGuinn, Katherine A High, Ype P de Jong, Amit Chhabra, Amanda O'Brien, Lynne M Smith und 2 weitere

New England Journal of Medicine · 17.04.2025 · 392 (15) · 1508-1517

DOI: 10.1056/nejmoa2307159 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 17.04.2025. Verfasst von John E J Rasko und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Sydney, Central Clinical School, Faculty of Medicine and Health, Sydney. Hauptthemen laut MEDLINE: Factor IX, Genetic Therapy, Hemophilia B, Hemorrhage. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX variant (FIX-R338L, or FIX-Padua) in a phase 1-2a study. The long-term safety and efficacy of this treatment are not known. METHODS: In a 12-month study, 15 participants with severe or moderately severe hemophilia B (factor IX coagulant activity, ≤2% of the normal value) received fidanacogene elaparvovec at a dose of 5×1011 vector genomes (vg) per kilogram of body weight; thereafter, participants could enroll in a 5-year follow-up study. Safety end points included adverse events and changes in laboratory measures. Efficacy end points included the annualized rate of treated bleeding events (annualized bleeding rate) and factor IX activity. RESULTS: A total of 14 participants provided consent and completed at least 3 years of follow-up (median, 5.5; range 3 to 6); participation was ongoing among 8 at the data cutoff. None of the participants reported treatment-related adverse events after year 1. Throughout follow-up, nine serious adverse events were noted in 4 participants; none were thrombotic or treatment-related. No factor IX inhibitors were detected. Throughout follow-up, mean factor IX activity was in the mild hemophilia range; the mean annualized bleeding rate was less than 1, and 10 participants had no treated bleeding episodes. Surveillance liver ultrasounds obtained from year 1 onward showed no evidence of cancer but showed steatosis in 4 participants who had weight gain and elevated aminotransferase levels (maximum alanine aminotransferase level, 77 U per liter). One participant with a history of hepatitis C, hepatitis B, human immunodeficiency virus infection, and an elevated body-mass index had progression of underlying advanced liver fibrosis. A total of 13 surgical procedures were performed in 8 participants; exogenous factor IX was administered for 10 procedures, and no associated unexpected bleeding complications occurred. CONCLUSIONS: Fidanacogene elaparvovec was associated with no or only low-grade adverse effects over a period of 3 to 6 years. Efficacy was maintained in the long term at 5×1011 vg per kilogram, one of the lowest intravenous doses of AAV used for any indication. (Funded by Pfizer; ClinicalTrials.gov number, NCT03307980.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXGenetic TherapyHemophilia BHemorrhageFatty LiverAdolescentAdultHumansMaleMiddle AgedYoung AdultDependovirusFollow-Up StudiesGenetic VectorsTreatment OutcomeGene Transfer TechniquesLiverAlanine TransaminaseLiver Function TestsUltrasonographySeverity of Illness Index

Substanzen

Factor IXAlanine Transaminase

Autor:innen und Institutionen

  • University of Sydney, Central Clinical School, Faculty of Medicine and Health, Sydney.
  • Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney.
  • Children's Hospital of Philadelphia, Philadelphia.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
  • Hemophilia Treatment Center, University of California, Davis, Sacramento.
  • St. Michael's Hospital, University of Toronto, Toronto.

ORCID-Profile: John E J Rasko

Förderung

  • Pfizer

Zitieren

APA

Rasko, J. E. J., Samelson-Jones, B. J., George, L. A., Giermasz, A., Ducore, J. M., Teitel, J. M., McGuinn, C. E., High, K. A., de Jong, Y. P., Chhabra, A., O'Brien, A., Smith, L. M., Winburn, I., & Rupon, J. (2025). Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study. New England Journal of Medicine, 392(15), 1508-1517. https://doi.org/10.1056/nejmoa2307159

Vancouver

Rasko JEJ, Samelson-Jones BJ, George LA, Giermasz A, Ducore JM, Teitel JM, et al. Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study. New England Journal of Medicine. 2025;392(15):1508-1517. doi:10.1056/nejmoa2307159

BibTeX
@article{Rasko2025,
  author = {Rasko, John E J and Samelson-Jones, Benjamin J and George, Lindsey A and Giermasz, Adam and Ducore, Jonathan M and Teitel, Jerome M and McGuinn, Catherine E and High, Katherine A and de Jong, Ype P and Chhabra, Amit and O'Brien, Amanda and Smith, Lynne M and Winburn, Ian and Rupon, Jeremy},
  title = {Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {15},
  pages = {1508--1517},
  doi = {10.1056/nejmoa2307159}
}
Kostenlos starten →